Literature DB >> 11400158

Characterization of tissue-specific LIM domain protein (FHL1C) which is an alternatively spliced isoform of a human LIM-only protein (FHL1).

E K Ng1, S M Lee, H Y Li, S M Ngai, S K Tsui, M M Waye, C Y Lee, K P Fung.   

Abstract

We have cloned and characterized another alternatively spliced isoform of the human four-and-a-half LIM domain protein 1 (FHL1), designated FHL1C. FHL1C contains a single zinc finger and two tandem repeats of LIM domains at the N-terminus followed by a putative RBP-J binding region at the C-terminus. FHL1C shares the same N-terminal two-and-a-half LIM domains with FHL1 but different C-terminal protein sequences. Due to the absence of the exon 4 in FHL1C, there is a frame-shift in the 3' coding region. Sequence analysis indicated that FHL1C is the human homolog of murine KyoT2. The Northern blot and RT-PCR results revealed that FHL1 is widely expressed in human tissues, including skeletal muscle and heart at a high level, albeit as a relatively low abundance transcript in brain, placenta, lung, liver, kidney, pancreas, and testis. In contrast, FHL1C is specifically expressed in testis, skeletal muscle, and heart at a relatively low level compared with FHL1. The expression of FHL1C transcripts was also seen in aorta, left atrium, left, and right ventricles of human heart at low level. Immunoblot analysis using affinity-purified anti-FHL1C antipeptide antibodies confirmed a 20 kDa protein of FHL1C in human skeletal muscle and heart. Unlike FHL1B, which is another FHL1 isoform recently reported by our group and localized predominantly in the nucleus [Lee et al., 1999], FHL1C is localized both in the nucleus and cytoplasm of mammalian cell. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11400158     DOI: 10.1002/jcb.1110

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  26 in total

1.  Genome-wide detection of tissue-specific alternative splicing in the human transcriptome.

Authors:  Qiang Xu; Barmak Modrek; Christopher Lee
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

2.  Negative control of keratinocyte differentiation by Rho/CRIK signaling coupled with up-regulation of KyoT1/2 (FHL1) expression.

Authors:  Maddalena Grossi; Agnès Hiou-Feige; Alice Tommasi Di Vignano; Enzo Calautti; Paola Ostano; Sam Lee; Giovanna Chiorino; G Paolo Dotto
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-01       Impact factor: 11.205

3.  Muscle lim protein isoform negatively regulates striated muscle actin dynamics and differentiation.

Authors:  Elizabeth Vafiadaki; Demetrios A Arvanitis; Vasiliki Papalouka; Gerasimos Terzis; Theodoros I Roumeliotis; Konstantinos Spengos; Spiros D Garbis; Panagiota Manta; Evangelia G Kranias; Despina Sanoudou
Journal:  FEBS J       Date:  2014-06-11       Impact factor: 5.542

4.  Dysregulation of FHL1 spliceforms due to an indel mutation produces an Emery-Dreifuss muscular dystrophy plus phenotype.

Authors:  Heather R Tiffin; Zandra A Jenkins; Mary J Gray; Sophia R Cameron-Christie; Jennifer Eaton; Salim Aftimos; David Markie; Stephen P Robertson
Journal:  Neurogenetics       Date:  2013-03-02       Impact factor: 2.660

5.  Influence of age, sex, and strength training on human muscle gene expression determined by microarray.

Authors:  Stephen M Roth; Robert E Ferrell; David G Peters; E Jeffrey Metter; Ben F Hurley; Marc A Rogers
Journal:  Physiol Genomics       Date:  2002-09-03       Impact factor: 3.107

6.  Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1.

Authors:  Joachim Schessl; Ana L Taratuto; Caroline Sewry; Roberta Battini; Steven S Chin; Baijayanta Maiti; Alberto L Dubrovsky; Marcela G Erro; Graciela Espada; Monica Robertella; Maria Saccoliti; Patricia Olmos; Leslie R Bridges; Peter Standring; Ying Hu; Yaqun Zou; Kathryn J Swoboda; Mena Scavina; Hans-Hilmar Goebel; Christina A Mitchell; Kevin M Flanigan; Francesco Muntoni; Carsten G Bönnemann
Journal:  Brain       Date:  2009-01-29       Impact factor: 13.501

7.  Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer.

Authors:  Ruben Pio; David Blanco; Maria Jose Pajares; Elena Aibar; Olga Durany; Teresa Ezponda; Jackeline Agorreta; Javier Gomez-Roman; Miguel Angel Anton; Angel Rubio; Maria D Lozano; Jose M López-Picazo; Francesc Subirada; Tamara Maes; Luis M Montuenga
Journal:  BMC Genomics       Date:  2010-06-03       Impact factor: 3.969

8.  Epigenetic analysis of FHL1 tumor suppressor gene in human liver cancer.

Authors:  Jun Wang; Fang Huang; Jian Huang; Jindan Kong; Shenglan Liu; Jun Jin
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

9.  Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy.

Authors:  Lucie Gueneau; Anne T Bertrand; Jean-Philippe Jais; Mustafa A Salih; Tanya Stojkovic; Manfred Wehnert; Maria Hoeltzenbein; Simone Spuler; Shinji Saitoh; Annie Verschueren; Christine Tranchant; Maud Beuvin; Emmanuelle Lacene; Norma B Romero; Simon Heath; Diana Zelenika; Thomas Voit; Bruno Eymard; Rabah Ben Yaou; Gisèle Bonne
Journal:  Am J Hum Genet       Date:  2009-08-27       Impact factor: 11.025

10.  Proteomic identification of FHL1 as the protein mutated in human reducing body myopathy.

Authors:  Joachim Schessl; Yaqun Zou; Meagan J McGrath; Belinda S Cowling; Baijayanta Maiti; Steven S Chin; Caroline Sewry; Roberta Battini; Ying Hu; Denny L Cottle; Michael Rosenblatt; Lynn Spruce; Arupa Ganguly; Janbernd Kirschner; Alexander R Judkins; Jeffrey A Golden; Hans-Hilmar Goebel; Francesco Muntoni; Kevin M Flanigan; Christina A Mitchell; Carsten G Bönnemann
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.